North American Nuclear Medicine Market Expected to Reach USD 2.7 Billion by 2024 with a CAGR of 4.1% – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.

The North American nuclear medicine market is projected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.

North American nuclear medicine market is projected to grow at a CAGR of 4.1%.

The North American nuclear medicine market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide. Growth in the market can primarily be attributed to factors such as increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99.

The Technetium-99m segment to hold the largest share of the SPECT radiopharmaceuticals market in 2019

Based on type, the SPECT Radiopharmaceuticals market is segmented into Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to hold the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80-90% of diagnostic scans and around 30 million patient examinations every year.

The endocrine tumours segment is projected to grow at the highest CAGR during the forecast period

Based on application, the North American nuclear medicine market is categorized into thyroid indications, bone metastasis, lymphoma, endocrine tumours, and other indications. The endocrine tumours segment is expected to be the fastest-growing application segment in the therapeutic nuclear medicine applications market. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumours.

The US to witness the highest growth during the forecast period

The North American nuclear medicine market is segmented into the US and Canada, based on country. The US is expected to register the highest CAGR during the forecast period. The growth of the market in the US can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.

Key Benefits of Buying the Report:

This report focuses on various levels of analysis - industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the North American nuclear medicine market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the North American nuclear medicine and garner greater market shares.

Key Topics Covered:

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.2.1 Market Scope

1.2.2 Markets Covered

1.2.3 Years Considered for the Study

1.3 Currency

1.4 Limitations

1.5 Stakeholders

2 Research Methodology

2.1 Research Data

2.2 Research Methodology Steps

2.2.1 Secondary Data

2.2.2 Primary Data

2.2.3 Primary Sources

2.2.4 Key Insights From Primary Sources

2.2.5 Market Size Estimation Methodology

2.2.6 Revenue Mapping-Based Market Estimation

2.2.7 Market Data Estimation and Triangulation

2.2.8 Assumptions of the Study

3 Executive Summary

4 Premium Insights

4.1 North American Nuclear Medicine Market Overview

4.2 Market, By Type, (2019)

4.3 North American Diagnostic Nuclear Medicine Procedures Market, By Type, 2019-2024

4.4 North American Therapeutic Procedures Market, By Type (2019-2024)

5 Market Overview

5.1 Introduction

5.1.1 Market Dynamics

5.1.2 Drivers

5.1.3 Restraints

5.1.4 Opportunities

6 North American Nuclear Medicine/ Radiopharmaceuticals Market: Pipeline Assessment

6.1 Introduction

6.2 Diagnostic Radioisotopes

6.3 Therapeutic Radioisotopes

7 North American Nuclear Medicine/ Radiopharmaceuticals Market, By Type

7.1 Introduction

7.2 Diagnostic Nuclear Medicine

7.3 Therapeutic Nuclear Medicine

8 North American Nuclear Medicine/Radiopharmaceuticals Market, By Application

8.1 Introduction

8.2 Diagnostic Applications

8.3 Therapeutic Applications

9 North American Nuclear Medicine/Radiopharmaceuticals Market: Procedural Volume Assessment

9.1 Introduction

9.2 Diagnostic Procedures

9.3 Therapeutic Procedures

10 North American Nuclear Medicine/Radiopharmaceuticals Market, By Country

10.1 Introduction

10.1.1 US

10.1.2 Canada

11 Competitive Landscape

11.1 Overview

11.2 Competitive Leadership Mapping

11.3 Competitive Scenario

12 Company Profile

12.1 Cardinal Health

12.2 GE Healthcare

12.3 Curium

12.4 Lantheus Medical Imaging, Inc.

12.5 Bayer AG

12.6 Bracco Imaging S.P.A.

12.7 Eczacibai-Monrol Nuclear Products

12.8 Nordion, Inc.

12.9 Advanced Accelerator Applications (AAA)

12.10 NTP Radioisotopes Soc, LTD.

12.11 Joint Stock Company Isotope

12.12 Northstar Medical Radioisotopes, LLC

12.13 Eckert & Ziegler

12.14 Jubilant Draximage, Inc.

12.15 Pharmalogic

12.16 Institute of Isotopes Co., LTD.

12.17 Sinotau Pharmaceuticals Group

12.18 Isotopia Molecular Imaging Limited

12.19 Shine Medical Technologies

12.20 Global Medical Solutions, LTD.

12.21 FDA Approved Radiopharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/6lkq8k

Link:
North American Nuclear Medicine Market Expected to Reach USD 2.7 Billion by 2024 with a CAGR of 4.1% - ResearchAndMarkets.com - Business Wire